

Characterization of a novel dual HCK/BTK PROTAC (DFCI-002-06) that demonstrates potent *in vitro* activity and shows robust degradation of HCK and BTK in xenografted MYD88-mutated tumors in murine models.

Amanda Kofides (1), John M. Hatcher (1, 2, 3), Xia Liu (1), Jinhua Wang (3), Nickolas Tsakmaklis (1), Hao Sun (1, 2), Maria L. Guerrero (1, 2), Christopher J. Patterson (1), Zachary Hunter (1, 2), Shayna Sarosiek (1, 2), Jorge J. Castillo (1, 2), Sara J. Buhrlage (3), Steven P. Treon (1, 2), Shirong Liu (1, 2)

Affiliations

(1) Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA

(2) Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

(3) Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.

Background

Activating mutations in MYD88 are prevalent in various B-cell malignancies, including Waldenström Macroglobulinemia (95-97%), primary CNS lymphoma (70-80%), ABC DLBCL (40%), marginal zone lymphoma (5-10%), and CLL (5-15%). Mutated MYD88 upregulates the SRC family member HCK, which serves as a master signal for multiple pro-survival cascades in mutated MYD88 lymphoma cells, including BTK pathways (Blood 127:3237-52; Blood Adv 4:141-153; Blood Adv 6:3332-38). Previously, we developed KIN-8194, a novel HCK kinase inhibitor that blocks both HCK and BTK and is active *in vitro* and *in vivo* in MYD88-mutated xenograft lymphoma models, including BTK^{Cys481Ser} ibrutinib-resistant models (Blood 138:1966-79, Leukemia 38:1570-1580). Proteolysis targeting chimeras (PROTACs) represent a novel approach for blocking kinase-based signaling, offering greater selectivity and sustained target inhibition over traditional kinase inhibitors. We evaluated our newly developed highly potent, selective, and bioavailable HCK/BTK-targeting PROTACs for treating MYD88-driven lymphomas.

Methods

A series of potent HCK/BTK PROTACs were developed. Biological efficacy screenings using the Cell Titer-Glo Luminescent Cell Viability Assay identified two compounds with IC₅₀ scores lower than KIN-8194. These were selected for further validation through flow cytometry-based quantitative assays, which verified apoptotic and cytotoxic effects on WM and MYD88-mutated lymphoma cell lines, as well as primary human bone marrow mononuclear cells (BMMCs), utilizing Annexin V and Propidium iodide (PI) staining. A pharmacodynamics (PD) study was completed on one of the most potent PROTACs using a MYD88-mutated TMD8 cell-xenografted murine model.

Results

We identified two novel PROTACs (DFCI-002-05 and DFCI-002-06) that exhibited potent degradation of HCK and BTK by western blot (**Figure 1A**). Both PROTACs demonstrated low IC₅₀ values (1-100 nM) in proliferation assays of MYD88-mutated BCWM.1 WM and TMD-8 ABC DLBCL cells (**Figure 1B**). Importantly, the dual HCK/BTK PROTACs induced high levels of apoptosis in MYD88-mutated BCWM.1 WM, HBL-1, and TMD8 ABC DLBCL cells (**Figure 1C**). Additionally, treatment of cultured bone marrow cells from a newly diagnosed WM patient with mutated MYD88 showed profound cell death and apoptosis induction in CD19⁺ cells by the PROTACs, especially DFCI-002-06, compared with Zanubrutinib and KIN-8194 (**Figure 1D**).

We then conducted a PD study using a MYD88-mutated TMD8 cell-xenograft murine model. DFCI-002-06 was administered orally once daily for five days at doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (**Figure 2A**). We measured the HCK and BTK levels in the tumor and found significant degradation of HCK and BTK in the tumor tissue (**Figure 2B**). Consistent with this, treatment with DFCI-002-06 at the given dosages achieved significant suppression in tumor growth (**Figure 2C**).

Conclusions

We characterized novel dual HCK/BTK PROTACs that demonstrate potent protein degradation of HCK and BTK, and induction of cell death and apoptosis in MYD88-mutated WM and ABC DLBCL cells, as well as in the CD19⁺ population of WM patient bone marrow cells. The PD study of PROTAC DFCI-002-06 demonstrated robust degradation of HCK and BTK in xenografted MYD88-mutated tumors in a murine model and exhibited potent tumor suppression. Our studies provide an advancement in dual HCK/BTK PROTACs for the treatment of MYD88-mutated lymphomas.

Figures:

Figure 1




Figure 1. A. Degradation of HCK and BTK by PROTACs DFCI-002-05 and DFCI-002-06 compared with KIN-8194, evaluated in BCWM.1 WM and TMD8 ABC-DLBCL cell lines by western blot. B. ATP-based Cell Titer-Glo Luminescent Cell Viability Assay assessment of candidate PROTACs (DFCI-002s) compared to HCK/BTK inhibitor KIN-8194. C. Evaluation of cell death and apoptosis induction by the PROTACs in MYD88-mutated cell lines at the concentration of 0.5 μ M. D. Evaluation of cell death and apoptosis induction by the PROTACs in the CD19⁺ cell population of bone marrow cells from an untreated, newly diagnosed WM patient.

Figure 2




Figure 2. PD study of HCK degrader DFCI-002-06 in a TMD8 cell-xenograft murine model. A. Design of the study. B. Verification of HCK and BTK degradation in the tumor tissue post treatment. C. Tumor growth curve.